Synthesis and Preclinical Evaluation of Radiolabeled [¹⁰³Ru]BOLD-100

• Main Authors: Barbara Happl (Author), Marie Brandt (Author), Theresa Balber (Author), Katarína Benčurová (Author), Zeynep Talip (Author), Alexander Voegele (Author), Petra Heffeter (Author), Wolfgang Kandioller (Author), Nicholas P. Van der Meulen (Author), Markus Mitterhauser (Author), Marcus Hacker (Author), Bernhard K. Keppler (Author), Thomas L. Mindt (Author)
• Format: Book
• Published: MDPI AG, 2023-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The first-in-class ruthenium-based chemotherapeutic agent BOLD-100 (formerly IT-139, NKP-1339, KP1339) is currently the subject of clinical evaluation for the treatment of gastric, pancreatic, colorectal and bile duct cancer. A radiolabeled version of the compound could present a helpful diagnostic...